| Name | Title | Contact Details |
|---|
Metavention is a venture-backed medical device company founded in 2012 that is developing a novel glucose control therapy for patients with type 2 diabetes. Metabolic Neuromodulation Therapy (MNT) is a simple cardiovascular procedure intended to modulate sympathetic nervous system activity in patients with Type 2 diabetes for the purpose of lowering blood glucose levels. MNT was developed based on published scientific data and extensive animal studies suggesting a link between elevated sympathetic nerve activity in the metabolic system and increased levels of blood glucose. MNT is currently being studied in human clinical trials and represents a potentially important new treatment option for patients with Type 2 Diabetes.
Left unchecked, two base rats, a male and a female, can result in 15,000 descendants in about 12 months. It`s easy to see how quickly this can lead to infestations and even population rebounds if just two rats are left behind after a knockdown program. That`s where we come in. We`re SenesTech, the rat fertility experts and the makers of ContraPest®, the first and only EPA-registered rat fertility restrictor impacting both male and female rats. We make it possible to target both ends of the lifecycle—birth and death—by adding fertility control to your integrated pest management (IPM) solution. Controlling the birth rate with ContraPest will magnify the success of your existing IPM protocols. ContraPest is the one-of-a-kind, innovative technology that targets the reproductive capabilities of both male and female Norway and roof rats. Sweet and fatty, it`s highly palatable like a “milkshake” rats can`t get enough of. By using ContraPest, you can reduce the rat population and keep it down because ContraPest works!
Oncology Care Associates is a Saint Joseph, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aziyo Biologics is a fully integrated, commercially oriented regenerative medicine company. Since its founding in 2015 the Company has expanded through acquisitions and strategic partnerships, creating a high growth commercial entity. Its proprietary products are used in orthopedic, cardiovascular and other medical specialties.
Dyadic uses its proprietary C1 platform technology to discover and develop novel genes and other biological products from eukaryotic organisms found in the full spectrum of the earth’s biodiversity. Once useful genes are isolated, Dyadic uses its integrated platform to manufacture specific proteins, doing so more rapidly and efficiently — and with a much higher rate of success than existing gene discovery systems. Dyadic leverages its proprietary technology platform to discover novel genes and biological products for use by its strategic partners, and to further its own R&D efforts. Dyadic seeks strategic alliances with major leaders in the agricultural, bioenergy, industrial enzyme, chemical and biopharmaceutical industries that have in-house genomic capabilities. Dyadic will also collaborate with companies whose genomic capabilities are limited, discovering and expressing biological materials for these strategic partners. In addition, Dyadic, using these proprietary systems, will continue to commercialize enzymes for use in targeted markets, including the animal nutrition, detergent, ethanol, pulp and paper, biopharmaceutical, starch and textile industries. Dyadic expects to generate revenue from its product sales, revenue generated from research and development services and funding as well as revenue generated from licensing and other strategic collaborations in the form of milestone and royalty payments.